Trader Brian Jones on Twitter: "Calithera Biosciences shares are trading higher after the company announced the FDA granted Fast Track designation for sapanisertib for the treatment of NRF2-mutated squamous lung cancer. Oct 3, 2022 8:30a ETBenzinga Stock Analysis" / Twitter

Calithera Biosciences shares are trading higher after the company announced the FDA granted Fast Track designation for sapanisertib for the treatment of NRF2-mutated squamous lung cancer. Oct 3, 2022 8:30a ETBenzinga Stock Analysis

1:56 PM · Oct 3, 2022Twitter Web App

Likes

Conversation